Texas Attorney General Sues Acetaminophen Makers Concerning Autism Assertions

Judicial Action
The Texas Attorney General, a Trump ally seeking election to US Senate, accused pharmaceutical manufacturers of hiding potential dangers of acetaminophen

The top legal official in Texas Ken Paxton is filing a lawsuit against the producers of acetaminophen, claiming the corporations hid alleged dangers that the drug posed to pediatric cognitive development.

The court filing arrives thirty days after Former President Trump advocated an unsubstantiated connection between using acetaminophen - also known as paracetamol - throughout gestation and autism in children.

Paxton is filing suit against the pharmaceutical giant, which previously sold the medication, the only pain reliever recommended for pregnant women, and the current manufacturer, which presently makes it.

In a declaration, he said they "misled consumers by making money from pain and marketing drugs ignoring the potential hazards."

Kenvue states there is no credible evidence linking Tylenol to autism.

"These manufacturers lied for decades, knowingly endangering millions to boost earnings," Paxton, a Republican, declared.

The company commented that it was "very worried by the perpetuation of misinformation on the safety of paracetamol and the likely effects that could have on the health of US mothers and children."

On its website, the company also mentioned it had "consistently assessed the pertinent research and there is insufficient valid information that indicates a established connection between taking acetaminophen and autism spectrum disorder."

Organizations representing medical professionals and healthcare providers agree.

The American College of Obstetricians and Gynecologists has declared acetaminophen - the primary component in acetaminophen - is a restricted selection for expectant mothers to treat discomfort and fever, which can pose major wellness concerns if ignored.

"In multiple decades of studies on the consumption of paracetamol in gestation, no reliable research has successfully concluded that the use of acetaminophen in any stage of pregnancy results in brain development issues in young ones," the group said.

This legal action cites recent announcements from the former administration in claiming the drug is allegedly unsafe.

Last month, the former president raised alarms from medical authorities when he instructed women during pregnancy to "resist strongly" not to consume Tylenol when unwell.

The FDA then released a statement that doctors should consider limiting the use of Tylenol, while also declaring that "a direct connection" between the medication and autism in young ones has remains unverified.

The Health Department head RFK Jr, who oversees the Food and Drug Administration, had promised in spring to undertake "extensive scientific investigation" that would identify the origin of autism in a limited time.

But experts cautioned that discovering a unique factor of autism spectrum disorder - thought by researchers to be the outcome of a complex mix of inherited and external influences - would not be simple.

Autism spectrum disorder is a type of permanent neurological difference and impairment that impacts how persons experience and interact with the world, and is recognized using physician assessments.

In his court filing, Paxton - who supports Trump who is campaigning for federal office - claims the manufacturer and J&J "intentionally overlooked and tried to quiet the science" around acetaminophen and autism.

The lawsuit seeks to make the companies "destroy any marketing or advertising" that states Tylenol is safe for pregnant women.

This legal action mirrors the concerns of a assembly of parents of children with autism spectrum disorder and ADHD who filed suit against the manufacturers of Tylenol in recently.

The court dismissed the legal action, saying research from the parents' expert witnesses was not conclusive.

Allison Bartlett
Allison Bartlett

A tech enthusiast and business strategist sharing insights on digital transformation and startup growth.